Biopharma Dealmakers, Published online: 01 December 2025; doi:10.1038/d43747-025-00106-1 ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced vaccine and therapeutic applications.
ExploRNA Therapeutics Sp. z o.o. Innovative mRNA therapeutics based on next-generation cap analogs. // Biopharma Dealmakers. – 2025. – DOI: 10.1038/d43747-025-00106-1. – URL: https://www.nature.com/articles/d43747-025-00106-1
ExploRNA Therapeutics Sp. z o.o (2025). Innovative mRNA therapeutics based on next-generation cap analogs. Biopharma Dealmakers. https://doi.org/10.1038/d43747-025-00106-1
ExploRNA Therapeutics Sp. z o.o. “Innovative mRNA therapeutics based on next-generation cap analogs.” Biopharma Dealmakers, 2025. doi:10.1038/d43747-025-00106-1.
@article{oo2025,
title = {Innovative mRNA therapeutics based on next-generation cap analogs},
author = {o.o., ExploRNA Therapeutics Sp. z},
journal = {Biopharma Dealmakers},
year = {2025},
doi = {10.1038/d43747-025-00106-1},
url = {https://www.nature.com/articles/d43747-025-00106-1}
}
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05030-x Comment on: ‘Association of accelerometer-monitored physical activity with incident cataract: epidemiological and genetic evidence’
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05032-9 NAION during incretin-based therapy: an optic nerve head still adapted to hypertension
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05016-9 Comparing refractive errors in CACNA1F and CABP4 -associated disease in a UK cohort
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05018-7 Comment on: ‘Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease’